- Dr. Dennis McBride brings
extensive experience in Neuroscience and its interface with
Information and Medical Technology
- Retired at a rank that is the civilian equivalent of a
senior flag officer from the United States Navy
RADNOR,
Pa., June 18, 2024 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the
"Company"), a clinical-stage biopharmaceutical company, today
announced that the Company has added Dr. Dennis McBride to its Board of Directors. Dr.
McBride brings deep experience in Neuroscience, Medical and
Information Technology and digital therapeutics to the Company.
"I am delighted to welcome Dennis to the Board of NRx. His
unique background in both Neuroscience and Medical Technology will
be an important asset to the company as we seek to develop more
advanced treatments for patients," said Dr. Jonathan Javitt,
Chairman and Chief Scientist of NRx. "I have worked with Dennis
previously on a highly successful digital therapeutic and know the
quality he brings to our company."
"I am proud to join the Board of NRx at such an exciting time
for the company – the opportunities have never been greater in
Neuroscience to advance and improve novel therapies," commented Dr.
McBride. "I look forward to using my experience to help advance its
strategy and further the development of NRx's impressive
pipeline of CNS products and leading its initiative in digital
therapeutics."
Dr. Dennis McBride has led
numerous national and international initiatives in neuroscience and
its interface with information technology, national security, and
medical technology/drug development both within the federal
government and in the private sector, three of which are now
multi-billion-dollar enterprises. He has formative experience in
CNS-focused digital therapeutics, having participated with NRx
founders in developing now military-proven digital therapeutic
technology for reduction of stress and depression. He was
instrumental to the founding of InQTel and other private
sector-focused initiatives.
Dr. McBride dedicated his Navy career to Aerospace Medicine and ergonomics,
during which he served in leadership roles at six
nationally-prominent laboratories, including the Defense Advanced
Research Projects Agency (DARPA), Naval Aerospace Medical Research
Lab, Naval Research Lab, the Office of Naval Research, and the
Naval Medical Research Institute. Upon retiring as a highly
decorated Navy Captain, he assumed leadership of the Potomac
Institute for Policy Studies, where he continues to serve as
President Emeritus. He then joined the National Defense University as a Professor to lead
the Center for Technology and National Security Policy, completing
his term as a Senior Executive-4 (Civilian equivalent to Vice
Admiral). Most recently, he served a tour of duty in the Office of
the Secretary of Defense. Dr. McBride has served as an
adviser to Cabinet Secretaries, US Congressional Committees, and to
corporate C-Suite executives. His educational background includes
the University of Georgia, Naval
Aerospace Medical Institute, the University of
Southern California, the London School
of Economics, and Harvard Business
School, earning a Ph.D. in experimental psychology and four
master's degrees.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical
company developing therapeutics based on its NMDA platform for the
treatment of central nervous system disorders, specifically
suicidal bipolar depression, chronic pain and PTSD. The Company is
developing NRX-101, an FDA-designated investigational Breakthrough
Therapy for suicidal treatment-resistant bipolar depression and
chronic pain. NRx has partnered with Alvogen and Lotus around the
development and marketing of NRX-101 for the treatment of suicidal
bipolar depression. NRX-101 additionally has potential to act as a
non-opioid treatment for chronic pain, as well as a treatment for
complicated UTI.
NRx has recently announced plans to submit a New Drug
Application for HTX-100 (IV ketamine), through Hope Therapeutics,
in the treatment of suicidal depression, based on results of
well-controlled clinical trials conducted under the auspices of the
US National Institutes of Health and newly obtained data from
French health authorities, licensed under a data sharing agreement.
NRx was awarded Fast Track Designation for development of ketamine
(NRX-100) by the US FDA as part of a protocol to treat patients
with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a
Specialty Pharmaceutical Company, wholly-owned by NRX
Pharmaceuticals focused on development and marketing of an
FDA-approved form of intravenous ketamine for the treatment of
acute suicidality and depression together with a digital
therapeutic-enabled platform designed to augment and preserve the
clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, among others,
statements regarding the proposed public offering and the timing
and the use of the proceeds from the offering. Forward-looking
statements generally include statements that are predictive in
nature and depend upon or refer to future events or conditions, and
include words such as "may," "will," "should," "would," "expect,"
"plan," "believe," "intend," "look forward," and other similar
expressions among others. These statements relate to future events
or to the Company's future financial performance, and involve known
and unknown risks, uncertainties and other factors that may cause
the Company's actual results to be materially different from any
future results, levels of activity, performance or achievements
expressed or implied by these forward-looking statements. You
should not place undue reliance on forward-looking statements since
they involve known and unknown risks, uncertainties and other
factors which are, in some cases, beyond the Company's control and
which could, and likely will, materially affect actual results,
levels of activity, performance or achievements. Any
forward-looking statement reflects the Company's current views with
respect to future events and is subject to these and other risks,
uncertainties and assumptions relating to the Company's operations,
results of operations, growth strategy and liquidity. More detailed
information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the
Company's most recent Annual Report on Form 10-K and other filings
with the Securities and Exchange Commission. Investors and security
holders are urged to read these documents free of charge on the
SEC's website at http://www.sec.gov. Except as may be required
by applicable law, The Company assumes no obligation to publicly
update or revise these forward-looking statements for any reason,
or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, whether
as a result of new information, future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-appoints-neuroscience-information-technology-and-medical-technology-veteran-to-its-board-of-directors-302175147.html
SOURCE NRx Pharmaceuticals, Inc.
